Skip to main content
. 2019 Mar 20;2019:8029863. doi: 10.1155/2019/8029863

Figure 2.

Figure 2

Total serum levels of soluble receptor activator nuclear factor kappa B ligand (sRANKL) in patients with ankylosing spondylitis (AS). (a) Concentrations of serum sRANKL in homozygous carriers of the RANKL CGC haplotype (rs7984870, rs9533155, and rs9525641) compared to those in homozygous carriers of the RANKL GCT haplotype. (b) Concentrations of serum sRANKL in AS with syndesmophyte formation compared with those without syndesmophyte formation (p = 0.0054, by Mann-Whitney U test).